skip to Main Content

COVID-19 Intel Center

As our healthcare industry works together to make near- and long-term decisions about COVID-19, our public health, vaccine, and policy experts are here to help decipher the facts and navigate downstream implications for the healthcare system.

Abby Moorman

New Federal Rule Could Affect Infusion Site of Care Amid COVID-19 Pandemic

The Centers for Medicare & Medicaid Services (CMS) issued a new Interim Final Rule (IFR) that is intended to allow additional beneficiaries, especially those who are at high-risk, to receive home infusions amid COVID-19 transmission concerns. Specifically, the CMS clarified the definition of “homebound” under the Medicare Home Health Benefit and temporarily suspended enforcement of the National and Local Coverage Determinations (NCD and LCD) related to home infusion services. Uncertainties remain as to how these new flexibilities will be utilized, as well as how these flexibilities could impact treatment outcomes.

Mitchell Finkel

COVID-19 Supply Chain Considerations

As the novel coronavirus disease (COVID-19) continues to change daily life, concerns about the impact on global supply chains and possible drug shortages have increased. Additionally, changes to FDA processes may limit its ability to perform essential drug related activities.

Chris Sloan

Podcast: E2 – Get the Facts on COVID-19: Patient Out-of-Pocket Costs

Tune into the second episode of our podcast series that focuses on COVID-19. In episode 2, Avalere experts discuss how Medicare, Medicaid, and commercial plans will address the patient out of pocket costs associated with COVID-19 testing and treatment. They also acknowledge how commercial manufacturers are addressing the shortage of tests and turnaround for COVID-19 testing in the US.

Back To Top